{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:37:19Z","timestamp":1793731039164,"version":"4.6.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Microchromosome maintenance protein-binding protein (MCMBP) is aberrantly expressed in cancers and proposed as a diagnostic marker and therapeutic target, but its role in pancreatic ductal adenocarcinoma (PAAD) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a comprehensive analysis of MCMBP in PAAD using multi-omics data resources, including TCGA, GTEx, CPTAC, GEO, GDSC, TIDE, HPA, MethSurv, DiseaseMeth, and LinkedOmicsKB. We examined its prognostic characteristics, epigenetic alterations, immune infiltration, immunotherapy response, and drug sensitivity. By integrating transcriptomic, proteomic, and phosphoproteomic data, we explored the biological functions and pathways of MCMBP. Sensitive drugs related to MCMBP were identified through the GDSC and Connectivity Map (CMap) drug libraries, with further functional insights obtained through GO and KEGG enrichment analyses. Potential mechanisms were investigated via gene functional experiments, phos-phorylation site predictions from LinkedOmicsKB, and protein expression validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pan-cancer analysis revealed that MCMBP overexpression correlates with poor prognosis, including in PAAD. Cox regression identified MCMBP as an independent prognostic factor for PAAD. Low DNA methylation and high m6A modification of MCMBP may promote PAAD progression and correlate with adverse prognosis. Ge-ne function and immune infiltration analyses indicated that high MCMBP expression is closely associated with immune-related pathways, tumor cell proliferation, survival, and immune cell differentiation, and may promote Treg accumulation and immune ch-eckpoint upregulation. PAAD patients with low MCMBP expression exhibited greate-r sensitivity to anti-PD-L1 immunotherapy, suggesting a potential synergistic effect o-f MCMBP expression with anti-PD-L1 treatment. High MCMBP expression was ass-ociated with sensitivity to Gemcitabine combined with Paclitaxel, as well as small mo-lecules such as Tozasertib and Motesanib. MCMBP knockdown inhibited PAAD cell proliferation, migration, invasion, and G1-S transition. Immunohistochemical results s-howed that high MCMBP expression correlated with elevated PD-L1 levels and redu-ced CD4+ T cell infiltration in PAAD, which significantly associated with poor prog-nosis. MCMBP modulated PD-L1 through activation of the JAK-STAT3 signaling pat-hway, thereby promoting PAAD progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overexpression of MCMBP may serve as a prognostic biomarker and p-otential therapeutic target in PAAD. It drives PAAD progression by activating the JAK-STAT3 pathway to upregulate PD-L1.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1621927","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:36:38Z","timestamp":1763534198000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Multiomics profiling Identifies MCMBP as a prognostic biomarker and a potential immune-related target in pancreatic ductal adenocarcinoma via the JAK\u2013STAT3 pathway"],"prefix":"10.3389","volume":"16","author":[{"given":"Xinghai","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.02.012","article-title":"PAAD: changing epidemiology and new appro-aches to risk assessment, early detection, and prevention","volume":"164","author":"Stoffel","year":"2023","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in PAAD: curr-ent and future perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5808","article-title":"Association of adjuvant chemo-therapy in patients with resected pancreatic adenocarcinoma after multiagent neo-adjuvant chemotherapy","volume":"9","author":"Sugawara","year":"2023","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1681","article-title":"Organoids derived from neoadjuvant FOLFIRINOX patients recapitulate therapy resistance in pancreatic ductal adenocarci-noma","volume":"27","author":"Farshadi","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug r-esistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist Updat"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1462496","article-title":"Genomic instability as a driver and sup-pressor of anti-tumor immunity","volume":"15","author":"Requesens","year":"2024","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in PAAD pathogenesis and th-erapeutic resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cells12232712","article-title":"Chromosomal instability-driven cancer p-rogression: interplay with the tumour microenvironment and therapeutic strategie-s","volume":"12","author":"Zheng","year":"2023","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41586-020-2842-3","article-title":"Equilibrium between nascent and parenta-l MCM proteins protects replicating genomes","volume":"587","author":"Sedlackova","year":"2020","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.77393","article-title":"MCMBP promotes the assembly of the MCM2\u20137 hetero-hexamer to ensure robust DNA replication in human cells","volume":"11","author":"Saito","year":"2022","journal-title":"Elife"},{"key":"B11","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3892\/ol.2020.12171","article-title":"Diagnostic and prognostic value of MCM3 and its int-eracting proteins in hepatocellular carcinoma","volume":"20","author":"Li","year":"2020","journal-title":"Oncol Lett"},{"key":"B12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.neo.2014.07.011","article-title":"Deregulation of the replisome factor MCMBP prompts oncogenesis in colorectal carcinomas through chromosomal in-stability","volume":"16","author":"Quimbaya","year":"2014","journal-title":"Neoplasia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1039\/nar\/gky1131","article-title":"STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome w-ide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2217\/epi-2017-0118","article-title":"MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data","volume":"10","author":"Modhukur","year":"2018","journal-title":"Epigenomics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12943-019-1066-3","article-title":"Molecular characterization and clinical relevance of m6-A regulators across 33 cancer types","volume":"18","author":"Li","year":"2019","journal-title":"Mol Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and st-romal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic anal-yses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0157-9","article-title":"Robust prediction of response to immune c-heckpoint blockade therapy in metastatic melanoma","volume":"24","author":"Auslander","year":"2018","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts sur-vival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-3971","article-title":"Targeting the TRIM14\/USP14 axis enhances immune-therapy efficacy by inducing autophagic degradation of PD-L1","volume":"84","author":"Liu","year":"2024","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1166860","article-title":"Targeting tumor immunosuppressive microenvironm-ent for PAAD immunotherapy: current research and future perspective","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.03.012","article-title":"Emerging noninvasive methylation b-iomarkers of cancer prognosis and drug response prediction","volume":"83","author":"Oliver","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12943-022-01704-8","article-title":"m6A methylation: a process reshaping the tumour i-mmune microenvironment and regulating immune evasion","volume":"22","author":"Cao","year":"2023","journal-title":"Mol Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13046-022-02273-w","article-title":"Combination therapy for PAAD: anti-PD-(L)1-base-d strategy","volume":"41","author":"Liu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.11.003","article-title":"Contemporary clinical trials in PAAD im-munotherapy targeting PD-1 and PD-L1","volume":"86","author":"Nagaraju","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061721","article-title":"Immune checkpoint inhibitors: A pro-mising choice for endometrial cancer patients","volume":"9","author":"Musacchio","year":"2020","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114567","article-title":"Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of PAAD by modifying the tumor microenvironm-ent","volume":"161","author":"Lin","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/bio-medicines11102812","article-title":"DLL3 is a progno-stic and potentially predictive biomarker for immunotherapy linked to PD\/PD-L axis and NOTCH1 in PAAD","volume":"11","author":"Lacalle-Gonzalez","year":"2023","journal-title":"Biomedicines"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1291106","article-title":"JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in PAAD","volume":"6","author":"Lu","year":"2017","journal-title":"Oncoimmunology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2017.06.001","article-title":"The JAK\/STAT3 axis: a comprehensive d-rug target for solid Malignancies","volume":"45","author":"Huynh","year":"2017","journal-title":"Semin Cancer Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade comb-ination therapy reduces tumour progression in murine models of PAAD","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1621927\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:36:39Z","timestamp":1763534199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1621927\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2025.1621927"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1621927","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1621927"}}